Our Leadership

Madrigal’s leadership team is comprised of individuals with proven track records developing multiple FDA-approved medicines and expertise in building and leading successful biopharmaceutical companies.

PAUL A. FRIEDMAN, M.D. Chairman and Chief Executive Officer


Chief Executive Officer

Mr. Sibold has more than 30 years of experience in the biopharmaceutical industry. Prior to joining Madrigal, he served as Executive Vice President, Specialty Care of Sanofi and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas and served as a member of the Sanofi Executive Committee. Previously, Mr. Sibold served as Chief Commercial Officer of Avanir Pharmaceuticals, President and CEO of Lycera Corp., and Senior Vice President U.S. Commercial for Biogen.

REBECCA TAUB, M.D. Director, Founder, Chief Medical Officer and President of Research & Development


Director, Founder, Chief Medical Officer and President of Research & Development

Dr. Taub has more than 20 years of experience leading drug development, including roles as Senior Vice President of R&D at VIA Pharmaceuticals, Vice President of Metabolic Disease Research at Hoffmann-La Roche, and leadership roles at Bristol Myers Squibb and DuPont Pharmaceuticals. She was also tenured Professor of Genetics and Medicine at the University of Pennsylvania and a Howard Hughes Investigator.

REBECCA TAUB, M.D. Director, Founder, Chief Medical Officer and President of Research & Development


Chief Financial Officer

Ms. Dier has spent more than 20 years in executive financial leadership roles in the biopharmaceutical industry, with deep experience in operational and strategic decision making, capital raising, financial planning and accounting (FP&A), global supply chain management, investor relations and business development. She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Ms. Dier serves on multiple boards and is a member of the Board of Advisors for the Anderson School of Management at the University of California, Los Angeles (UCLA).

ROBERT WALTERMIRE, PH.D. Chief Pharmaceutical Development Officer


Chief Commercial Officer

Ms. Huntsman has more than 30 years of biopharmaceutical experience with 35 launches across immunology, neurology, oncology, rare diseases, and rare blood disorders. Prior to joining Madrigal, she served as the Senior Vice President, Head of Specialty Care North America and the U.S. Country Lead at Sanofi, where she was responsible for many specialty product launches, including the U.S. Launch of Dupixent. She held commercial roles of increasing responsibility at Sanofi Genzyme, EMD Serono, Pfizer and Muro Pharmaceuticals. Prior to joining the biopharmaceutical industry, Ms. Huntsman served as an officer in the U.S. Army.

BRIAN J. LYNCH General Counsel


Chief Human Resources Officer

Mr. Wallace brings more than 30 years of multi-industry experience to Madrigal’s Human Resources function. Most recently, he served as the Global Senior Vice President, People Functions & Organizations, at Kenvue, Inc., formerly the Consumer Healthcare division of Johnson & Johnson. Prior to Kenvue, Mr. Wallace served as Senior Vice President of Human Resources North America at Sanofi, and held roles of increasing responsibility at BASF Corporation, GE Healthcare and Pratt & Whitney. Mr. Wallace was a Commissioned Officer in the U.S. Air Force and retired in 2008 after 21 years of service.

ROBERT WALTERMIRE, PH.D. Chief Pharmaceutical Development Officer


Chief Information Officer

Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and digital transformation across core operations. From 2008 to 2021, Mr. Filippo held positions of increasing responsibility at Teva Pharmaceuticals from R&D through Commercial, most recently as Head of Data and AI Transformation for North America. Mr. Filippo began his career in the biopharmaceutical industry at Schering-Plough, supporting information technology operations in R&D and Quality.

STEPHEN DODGE, PHARM D, M.B.A. Senior Vice President, Global Medical Affairs


Senior Vice President, Global Medical Affairs

Dr. Dodge has over 20 years of medical affairs leadership across both small biotech and large pharma, including roles at Intercept, Merck, Novo Nordisk and Novartis. He has more than 10 years working directly in hepatology and GI, as well as metabolic disease, building out medical affairs capabilities to support market entry in new therapeutic areas across 20+ launches.

ROBERT WALTERMIRE, PH.D. Chief Pharmaceutical Development Officer


Chief Compliance Officer

Ms. Kelley has more than 20 years of diverse healthcare experience as a compliance and legal professional which will support Madrigal’s responsible growth. She joined Madrigal from Sanofi, where she served in roles of increasing responsibility. She was most recently Vice President, Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel for Boston Scientific Corporation. Earlier in her career, she spent ten years in enforcement roles with the U.S. Federal Government. Ms. Kelley was a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney’s Office for the District of Massachusetts focused on healthcare matters. She is a member of the Massachusetts, D.C. and Federal bars.

DOMINIC F. LABRIOLA, PH.D. Chief Data and Analytics Officer


Chief Business Officer

Mr. Barrett brings more than 25 years of executive leadership and biopharmaceutical industry experience to Madrigal, with a track record of success completing a wide range of partnerships and acquisitions to build commercial portfolios and R&D pipelines across therapeutic areas. Most recently, he was CEO, Co-founder, and Director of Lassen Therapeutics, a biotechnology company focused on development of novel antibody therapeutics in immunological diseases and cancer. Mr. Barrett also served as Entrepreneur in Residence at Frazier Healthcare Partners, where he focused on starting and financing new biotech companies. Prior to Lassen, he held leadership positions in Strategy and Business Development at Johnson & Johnson and Sanofi.

The Madrigal Leadership Team is committed to improving care for patients with NASH.